Company Profiles

Print
 




http://www.jazzpharma.com/
EUSA Pharma GmbH,
Grillparzerstraße 18, 81675 Munich
Tel.: +49 89 411 096 60,
Fax: +49 89 411 096 61.
The International Division (ex-US) of Jazz Pharmaceuticals plc, is a specialty biopharmaceutical company that identifies, develops and commercialises differentiated medicines to address unmet medical needs in focussed therapeutic areas related to haemato-oncology and haematopoietic stem-cell transplantation. We are dedicated to help make a difference in patients' lives through our innovative medicines, passion, collaboration and pursuit of excellence.

Neovii Biotech GmbH
Am Haag 6
82166 Graefelfing
Germany
Tel.: +49 89 89 8888-0
info@neovii-biotech.com
Neovii Biotech GmbH is a globally operating company dedicated to delivering targeted biopharmaceutical treatment options in transplantation medicine. A focal point of activity is the development and commercialization of immunologically active therapeutics. For 30 years Neovii Biotech has been manufacturing and commercializing ATG-Fresenius. In the near future this well known drug will be marketed as GRAFALON. ATG Fresenius (GRAFALON) is a medicinal product for the prevention and treatment of acute organ rejection after solid organ transplantation and for the prevention of Graft-versus-Host-disease after stem cell transplantation.
One Health Plaza, East Hanover,
NJ 07936-1080
USA- Tel: +1 862 778 21 00
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates and sell products in more than 150 countries around the world.
Novartis Pharmaceuticals has created a dedicated unit focused on the development and commercialization of Cell and Gene Therapies. The cell therapy portfolio aims to transform medical practice and potentially cure some patients suffering from a variety of life threatening diseases including blood borne cancers, sickle cell disease, thalassemias and other diseases by replacing, repopulating or resetting the immune system.


For more information, please contact MSD at: phone +49 800 673 673 673; fax: +49 800 673 673 329;
Mail:
Infocenter@msd.de;
Internet:
http://www.msd.de/

About MSD:
MSD is part of Merck & Co., Inc., headquartered in Kenilworth, NJ, USA – a global health care leader. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Furthermore, MSD is aiming to enhance global health care and to improve access to health care through far-reaching health care policies, programs, and partnerships. In Germany, MSD is located in Haar near Munich.



RIEMSER Pharma GmbH
An der Wiek 7
17493 Greifswald-Insel Riems
Germany

phone +49 30 338427-0
e-mail info@RIEMSER.com
www.RIEMSER.com
RIEMSER Pharma GmbH, headquartered in Greifswald, Germany, is a midsize pharmaceutical company specialized in marketing and sophisticated life cycle management of specialty drugs for treatment of highly complex and niche disease areas. RIEMSER targets European markets but its products are distributed worldwide by a wide-ranging partner network.
 


Sanofi-Aventis Deutschland GmbH
Potsdamer Str. 8
10785 Berlin
www.sanofi.de
Kontakt.de@sanofi.com
Tel. +49 – 30 – 2575 2000
About Sanofi Oncology
Sanofi Oncology, a global division of Sanofi, is dedicated to the discovery, development and
delivery of effective therapeutics that address unmet medical need for cancer patients. We are building a renewed and diversified oncology portfolio, driven by the principles of innovation, personalization and patient access to medicines. Through partnerships and collaborations with leading experts in the areas of research, clinical practice, patient experience and patient access.
Sanofi Oncology aims to deliver innovative treatment solutions that provide meaningful benefit to patients around the world. We are currently marketing 10 products to address select solid tumors, hematological conditions and organ transplantation.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions
focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 
 
 


Celgene GmbH
Joseph-Wild-Straße 20
81829 München (Germany)
Telefon: +49 (0) 89 4 51 51 9 - 010
Telefax: +49 (0) 89 4 51 51 9 - 019
E-Mail: info@celgene.de
Web: www.celgene.de
Celgene Corporation and its subsidiaries is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. For more information, please visit the company's Web site at www.celgene.com.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
GILEAD Sciences GmbH
Fraunhoferstr. 17
8251 Martinsried

 


Tel.: +49 (0)4103 8006-0
Fax: +49 (0)4103 8006-100
E-Mail: contact@medac.de

medac is specialised in the treatment of malignant diseases since its foundation in 1970. Now, medac isone of the leading manufacturers of oncology products not only in Germany, but in many international markets. medac offers both, innovative and well proven, therapeutic options in the fields of Oncology, Hematology, Urology, Autoimmune diseases
and Fibrinolysis and is one of a handful of companies which is also specialised in the field of diagnostics.

PIERRE FABRE MEDICAMENT
45 place Abel Gance
923654 Boulogne Billancourt
TEL +33 (0) 1 49 10 80 00
www.pierre-fabre.com
Pierre Fabre is the third french largest pharmaceutical laboratory. The group has subsidiaries in 44 countries and distribution agreements in over 130 countries. Present in all healthcare segments, from ethical pharmaceuticals to dermo-cosmetic products and OTC drugs, Pierre Fabre devoted over 17% of its revenue from pharmaceuticals to R&D, in three main areas of research: oncology, dermatology and neuropsychiatry.
Through the holding company Pierre Fabre Participations, 86% of Laboratoires Pierre Fabre are held by the Pierre Fabre Foundation, recognized as a public-interest foundation since 1999.
For further information, visit our website:
www.pierre-fabre.com




Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development.
For information on Ribomustin in Israel please contact: info@astellas.co.il

Janssen-Cilag GmbH
Johnson & Johnson Platz 1
41470 Neuss
+49 2137 955 0 tel
+49 2137 955 327 fax
jancil@its.jnj.com
www.janssen-cilag.de
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., psoriasis), neuroscience (e.g., schizophrenia, dementia and pain) and infectious disease (e.g., HIV/AIDS, hepatitis C and tuberculosis). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.






URL:
www.miltenyibiotec.com
Email: macs@miltenybiote.de
Address: Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany
Phone: +49 2204 8306 0
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative portfolio supports scientists and clinicians at every level, from basic research to translational research to clinical application. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,400 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

Tel: +49 30 2639 288 0
Fax: +49 30 2639 28820
Address: Am Karlsbad 15, 10785 Berlin, Germany
URL:
www.pirche.org
Email:
thomas.bart@cytolon.com/ laura.ruiz@cytolon.com
University Medical Center (UMC) Utrecht has developed a new method (PIRCHE / Predicted Indirectly ReCognized HLA Epitopes) to select permissible, single mismatch donors in hematopoietic stem cell transplantation (HSCT), which may be as good as a 10/10 match.
We consider PIRCHE to be a breakthrough technology. PIRCHE allows the selection of mismatch donors in cases where a perfect match is not available. This might open up significant new avenues in the field of hematopoietic and solid organ transplantation.
The PIRCHE module is fully functional and already available for interested parties. We are currently performing its clinical validation with international partners.
 
Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development.


Biotype Diagnostic GmbH
Moritzburger Weg 67
01109 Dresden, Germany
Tel: +49 (0)351 8838 400
E-Mail:
info@biotype.de
URL: http://www.biotype.de
Biotype Diagnostic develops, produces and sales molecular CE/IVD multiplex-solutions to assess the course of AML disease and to monitor HSCT engraftment. Beside the field of Haematology /Oncology Biotype provides molecular diagnostics for Dermatology. The company's knowhow is built on longstanding experience in developing and manufacturing DNA-analytical devices. Biotype Diagnostic is specialized on multiplexing, giving many complex parameters one routine-fit and reliable read-out. In close collaboration with clinical partners Biotype continuously transfers scientific know-how into marketable products and paves the way for expert diagnostics with individual and comprehensive customer support and training.


Cell Medica Ltd
1 Canal Side Studios
8-14 St Pancras Way
London, NW1 0QG

Tel: +44 (0)20 7554 4070
E-mail: info@cellmedica.co.uk

Cell Medica Ltd is a leading commercial stage cellular therapeutics company developing, manufacturing and marketing personalized immunotherapies for the treatment of virus-associated lymphomas and viral infections after reactivation post hematopoietic stem cell transplant. Headquartered in London, Cell Medica's fully licensed GMP facility is located in Berlin, Germany and US operations are based in Houston, Texas.
Cell Medica's lead product, CytovirTM CMV, are directly selected CMV-specific T cells, commercially available in the UK, Ireland and Germany.
 
The International Division (ex-US) of Jazz Pharmaceuticals plc, is a specialty biopharmaceutical company that identifies, develops and commercialises differentiated medicines to address unmet medical needs in focussed therapeutic areas related to haemato-oncology and haematopoietic stem-cell transplantation. We are dedicated to help make a difference in patients' lives through our innovative medicines, passion, collaboration and pursuit of excellence. For more information on our products please visit www.jazzpharma.com or contact us: EUSA Pharma GmbH, Grillparzerstraße 18, 81675 Munich, Tel.: +49 89 411 096 60, Fax: +49 89 411 096 61.

Neovii Biotech GmbH
Am Haag 6
82166 Graefelfing
Germany
Tel.: +49 89 89 8888-0
info@neovii-biotech.com
Neovii Biotech GmbH is a globally operating company dedicated to delivering targeted biopharmaceutical treatment options in transplantation medicine. A focal point of activity is the development and commercialization of immunologically active therapeutics. For 30 years Neovii Biotech has been manufacturing and commercializing ATG-Fresenius. In the near future this well known drug will be marketed as GRAFALON. ATG Fresenius (GRAFALON) is a medicinal product for the prevention and treatment of acute organ rejection after solid organ transplantation and for the prevention of Graft-versus-Host-disease after stem cell transplantation.


www.teva.de
Teva GmbH
Graf-Arco-Straße 3
89079 Ulm
Tel.: +49 731 402 02
Fax: +49 731 402 78 32
info.teva-deutschland@teva.de
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), headquartered in Israel, is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Teva's net revenues in 2014 amounted to $20.3 billion.
In Germany, Teva supplies innovative medicines, branded products, generics and over-the-counter medications, all under one umbrella. This is unusual in the pharmaceuticals industry and therefore makes the company stand out from the rest.The company also focusses on the area of cancer treatments.Over the past year in this field, Teva has successfully launched in Germany a biotechnologically manufactured medicine. The development and manufacture of biotechnology drugs are generally given a high priority at Teva.



Therakos (UK) Limited
Wellington Road, Wokingham
Berkshire RG 40 2AT
United Kingdom
Tel: +44 (0)118 315 0810
Website:
www.therakos.com
info@therakos.com
Therakos is an immunotherapy company focused on providing innovative treatment platforms that harness the power of each individual patient's immune system to fight disease. We are the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP). Our therapeutic platforms, including the latest generation THERAKOS® CELLEX® Photopheresis System, are the world's only approved, fully-integrated systems for administering autologous immune cell therapy through extracorporeal photopheresis (ECP). Our systems are used by academic medical centres, hospitals, and treatment centres in more than 30 countries and have already delivered over one million treatments globally.



Helmholtzstraße 10, 89081 Ulm
Postbox 4244, 89032 Ulm
Fon +49-731-1507-000
Fax +49-731-1507-500
info@zkrd.de
www.zkrd.de

The ZKRD - the German National Registry of Blood Stem Cell Donors is the nation's information hub in searching for an unrelated blood stem cell donor. Data from all over Germany pertaining to the search for an unrelated donor converges here. The search is organized at a national and international level in order to assure that this complex process operates as quickly, efficiently, transparently and economically as possible. It coordinates the whole process and checks all related requests and results for completeness and plausibility. Based on the number of donors identified annually for transplantation, then the ZKRD is one of the most productive registries worldwide.